Irofulven

Xi'an Faithful BioTech Co., Ltd: Your Trusted Irofulven Manufacturer & Supplier

Xi'an Faithful BioTech Co., Ltd. sells Irofulven. Xi'an Faithful BioTech Co., Ltd. To establish a foothold in the market, we attach great importance to product quality. We usually establish a strict quality control system and follow international production standards. Moreover, as people's living standards improve, the demand for health foods and health products increases. For instance, vitamin C raw powder, as a food additive and raw material for health products, has seen a continuous rise in demand. Our production is also constantly expanding.

Irofulven Introduction

Irofulven is a melanocortin 4 receptor (MC4R) agonist that acts on the melanocortin 4 receptor in humans and rats. The mechanism by which it activates MC4R may be different from that of natural ligands and first-generation synthetic agonists. It may exert its effect by antagonizing naturally occurring neurotransmitters that inhibit the activation of MC4R. It has been confirmed that its therapeutic effect on obesity is positive and has reached the phase 3 clinical endpoint. Irofulven is a semi-synthetic anticancer drug, derived from the natural toxin Illudin S, found in the Jack-o'-lantern mushroom (Omphalotus illudens). It functions as a DNA alkylating agent, binding to DNA and protein macromolecules, leading to cell cycle arrest in the S-phase and programmed cell death (apoptosis). Irofulven is known for its activity against a broad range of human tumors and its ability to overcome resistance to other alkylating agents.

Email: sales9@faithfulbio.com

COA

Why Choose Us?

1. With stable production/procurement channels, Irofulven can ensure long-term and continuous supply, avoiding the impact on customers' R&D or production progress due to raw material shortages.Hidden cost savings: We offer standardized procurement processes and support unified invoicing, helping you reduce communication costs for procurement personnel and financial accounting time.
2. With a professional logistics system, we can provide low-temperature storage (-20°C, meeting Irofulven storage conditions) and full-process temperature-controlled transportation according to your needs to ensure the stable quality of the goods upon delivery.
3. Under the premise of ensuring quality, we offer market-competitive prices to help customers control R&D or production costs.
4. Establish a complete after-sales system. In case of quality problems, we can respond and handle them in a timely manner to protect the rights and interests of customers. For long-term cooperative customers, we can provide better cooperation plans.

Application Areas

• Pancreatic cancer: By activating signaling pathways such as JNK1 and Erk1/2, inducing apoptosis of pancreatic cancer cells, especially for pancreatic cancer with limited efficacy from traditional chemotherapy, is one of the important research directions.

• Ovarian cancer: In Phase II clinical trials, certain therapeutic effects were demonstrated in some patients with recurrent ovarian cancer, providing a potential option for the treatment of drug-resistant or recurrent ovarian cancer (attention should be paid to the management of adverse reactions such as retinal toxicity).

• Other solid tumors: The research also involves solid tumors such as breast cancer, colorectal cancer, and non-small cell lung cancer, exploring their efficacy as monotherapy or in combination with other chemotherapy drugs to enhance anti-tumor activity and reduce drug resistance.

Quality Control:

R&D Results:

Packaging and Transportation:

After-Sales Service:

Qualification Certification:

Transaction Feedback:

Exhibition:

FAQ

Q1: How is Irofulven progressing in clinical research on tumor treatment at present, and which types of cancer does it mainly target?

A1: Research on ovarian cancer, pancreatic cancer, prostate cancer, and other solid tumors also involves the study of solid tumors such as breast cancer, colorectal cancer, and non-small cell lung cancer, exploring their efficacy in monotherapy or in combination with other chemotherapy drugs to enhance anti-tumor activity and overcome drug resistance issues. However, most of them are still in the research stage and have not yet received wide clinical application approval.

Q2: What adverse reactions may patients experience when treated with Irofulven and how to deal with these adverse reactions?

A2: Visual symptoms: They are quite prominent, such as flashes of light, blurred vision, photosensitivity, etc., and the incidence and severity of these symptoms are dose-related. In terms of countermeasures, doctors need to closely monitor changes in the patient's vision and suspend medication if necessary. Patients should avoid strong light stimulation in their daily life and wear protective equipment such as sunglasses when going out.

Gastrointestinal reactions: Common symptoms include nausea, vomiting, anorexia, etc. Vomiting symptoms can be relieved by using antiemetic drugs. At the same time, nutritional support should be provided to the patient, encouraging them to have small and frequent meals and choose easily digestible and nutrient-rich foods.

Hematological toxicity: such as bone marrow suppression, manifested as neutropenia, thrombocytopenia and anemia, etc., which may be more obvious when used in combination. Doctors need to monitor blood routine tests regularly. Depending on the degree of blood cell reduction, they may take measures such as using drugs that promote blood cell production or suspending treatment.

Other symptoms such as fatigue and mucositis may also occur. For fatigue, patients need to ensure adequate rest and, if necessary, engage in appropriate rehabilitation activities. For mucositis, symptoms can be alleviated by maintaining oral hygiene and using mucosal protectants, among other methods.

Q3: How Irofulven works？

A3: DNA and Protein Alkylation:
Irofulven attaches to DNA and protein macromolecules, forming adducts that block cancer cell growth and function.
Metabolic Activation:
Its activity depends on bioactivation by the alkenal/one oxidoreductase (AOR) enzyme, which is often highly expressed in tumors.
Multifaceted Cytotoxicity:
Beyond DNA modification, irofulven also causes cell death through mechanisms such as generating reactive oxygen species and promoting mitochondrial dysfunction.
Overcoming Resistance:
Irofulven has shown activity against tumor cells that are resistant to other anti-cancer agents, in part because it is not readily deactivated by common resistance mechanisms.

Contact Us

Are you ready to use our high-quality Irofulven? Contact our expert team today to discuss your needs and discover how Xi'an Faithful BioTech can support your business growth.

Email: sales9@faithfulbio.com

Let’s work together to turn your goals into reality.